Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor β

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 9, 2009, Pages 2404-2408

  Sarachine, Miranda J ^a   Janjic, Jelena M ^b   Wipf, Peter ^b   Day, Billy W ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antiproliferative; Chemical synthesis; Estrogen receptor; Receptor binding

Indexed keywords

ALIPHATIC AMINE; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE REGULATION; CELL LINE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL;

AMIDES; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; ESTROGEN RECEPTOR BETA; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MODELS, CHEMICAL; PROTEIN BINDING; PROTEIN ISOFORMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64249131440     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.075     Document Type: Article

References (27)

1. Sun J., Baudry J., Katzenellenbogen J.A., and Katzenellenbogen B.S. Mol. Endocrinol. 17 (2003) 247
2. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engström O., Ljunggren J., Gustafsson J.A., and Carlquist M. EMBO J. 18 (1999) 4608
3. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., and Gustafsson J.A. Endocrinology 138 (1997) 863
4. Ström A., Hartman J., Foster J.S., Kietz S., Wimalasena J., and Gustafsson J.A. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1566
5. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., and Leitman D.C. Cancer Res. 64 (2004) 423
6. Hartman J., Lindberg K., Morani A., Inzunza J., Ström A., and Gustafsson J.A. Cancer Res. 66 (2006) 11207
7. Cho M.A., Lee M.K., Nam K.H., Chung W.Y., Park C.S., Lee J.H., Noh T., Yang W.I., Rhee Y., Kim S.K., Lee H.C., and Lee E.J. J. Endocrinol. 195 (2007) 255
8. Ji Q., Liu P., Elshimali Y., and Stolz A. Mol. Cell Endocrinol. 229 (2005) 103
9. Pravettoni A., Mornati O., Martini P.G., Marino M., Colciago A., Celotti F., Motta M., and Negri-Cesi P. Mol. Cell Endocrinol. 263 (2007) 46
10. Chan K.K., Wei N., Liu S.S., Xiao-Yun L., Cheung A.N., and Ngan H.Y. Obstet. Gynecol. 111 (2008) 144
11. Harris H.A., Albert L.M., Leathurby Y., Malamas M.S., Mewshaw R.E., Miller C.P., Kharode Y.P., Marzolf J., Komm B.S., Winnekar R.C., Frail D.E., Henderson R.A., Zhu Y., and Keith J.C.Jr. Endocrinology 144 (2003) 4241
12. Boos G., and Stopper H. Toxicol. Lett. 116 (2000) 7
13. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., and Katzenellenbogen J.A. J. Med. Chem. 44 (2001) 4230
14. Edsall Jr. R.J., Harris H.A., Manas E.S., and Mewshaw R.E. Bioorg. Med. Chem. 11 (2003) 3457
15. Yang C., Edsall Jr. R., Harris H.A., Zhang X., Manas E.S., and Mewshaw R.E. Bioorg. Med. Chem. 12 (2004) 2553
16. Janjic J.M., Mu Y., Kendall C., Stephenson C.R., Balachandran R., Raccor B.S., Lu Y., Zhu G., Xie W., Wipf P., and Day B.W. Bioorg. Med. Chem. 13 (2005) 157
17. Wipf P., Coleman C.M., Janjic J.M., Iyer P.S., Fodor M.D., Shafer Y.A., Stephenson C.R., Kendall C., and Day B.W. J. Comb. Chem. 7 (2005) 322
18. The ER competitor assays were performed according to the manufacturer's (Invitrogen, Carlsbad, CA) recommendations with some modifications. Human recombinant ER was used at the recommended concentration of 15 nM and the Fluormone™ ES2 was used at a concentration of 1 nM. Aliquots (20 μL) of the mixture of ER and Fluormone™ ES2 were distributed in 384-well, black flat-bottom plates and serial dilutions of test compounds in DMSO were added. Each compound was tested in duplicate, and 1 μM E2 was used as a positive control. The DMSO concentration was kept at 1% (v/v) throughout the experiment. After 2 h, the fluorescence polarization (FP) was measured using an Analyst™ AD & HT Assay Detection Systems reader (Molecular Devices, Sunnyvale, CA) equipped with 485 nm excitation and 530 nm emission filters with the appropriate FL505 dichroic mirror. Data was then analyzed by linear regression using GraphPad Prism's one-site competition method. The fit was constrained by the high polarization control, which was the ER/ES2 complex with no competition, and the low polarization control, which was the ER/ES2 complex with 1 μM E2 for 100% competition.
19. Tao B., and Boykin D.W. Tetrahedron Lett. 44 (2003) 7993
20. De Angelis M., Stossi F., Carlson K.A., Katzenellenbogen B.S., and Katzenellenbogen J.A. J. Med. Chem. 11 (2005) 1132
21. 50 values.
22. Thompson E.W., Reich R., Thomas T.B., Albini A., Graf J., Martin G.R., Dickson R.B., and Lippman M.E. Cancer Res. 48 (1988) 6764
23. Cailleau R., Olivé M., and Cruciger Q.V. In Vitro 14 (1978) 911
24. 3 cells/well and allowed to adhere for 72 h in phenol red-free RPMI-1640 containing 10% FBS. Test agents were added (concentrations ranging from 3.2 nM to 50 μM) and cells were incubated for 72 h. Cell density was determined using the MTS assay as described above.
25. Liao D.J., and Dickson R.B. Endocrine-Related Cancer 7 (2000) 143
26. Dubik D., Dembiniski T.C., and Shiu R.P. Cancer Res. 47 (1987) 6517
27. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., and Katzenellenbogen J.A. J. Med. Chem. 43 (2000) 4934